search
Back to results

The Effect of Nebulization of Alkaline Solution on Treating XDRAB Pneumonia With C/S Plus Minocycline (NAEDRAP)

Primary Purpose

Pneumonia

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
C/S plus minocycline.
nebulization with pH 7.4 solution
nebulization with pH 7.8 solution
No nebulization
Sponsored by
Xijing Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pneumonia focused on measuring Extensively Drug Resistant A. Baumannii

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age: 18 to 75 years old, male or female
  • The pneumonia patients met the diagnostic criteria, and clinical pulmonary infection score (CPIS) ≥ 5;
  • The sputum bacteriology detection only prompted Acinetobacter baumannii culture for pathogens concentration meets the diagnostic criteria of the Chinese hospital-acquired pneumonia diagnosis and treatment guidelines, 2002 edition of "Acinetobacter baumannii and susceptibility results show only 1 to 2 sensitive to antimicrobial drugs (polymyxin, minocycline or tegafur doxycycline);
  • Cephalosporins or tetracyclines drug treatment without a history of allergies and contraindications;
  • Be able to accept inhalation therapy.
  • Informed consent gained

Exclusion Criteria:

  • Refused to accept inhalation therapy
  • Renal insufficiency, creatinine clearance (Cockcroft-Gault formula) (CLcr) 15 ml / min or less;
  • Liver dysfunction, defined as Child-Pugh score B or C
  • Within one week before the start of cefoperazone sulbactam, minocycline treatment.

Sites / Locations

  • Xijing Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Sham Comparator

Active Comparator

Experimental

Arm Label

no nebulization

nebulization with pH 7.4 solution

nebulization with pH 7.8 solution

Arm Description

Antibiotics protocol is C/S plus minocycline. That is Cefoperazone/ sulbactam 3.0g(intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral,q12h).No nebulization will given to these patients.

Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.4 solution(Each time the volume of aerosol solution is 5ml, q8h).

Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.8 solution(Each time the volume of aerosol solution is 5ml, q8h).

Outcomes

Primary Outcome Measures

Pathogenic Clearance rate and recovery rate

Secondary Outcome Measures

adverse reaction rate

Full Information

First Posted
March 10, 2013
Last Updated
February 9, 2014
Sponsor
Xijing Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02060149
Brief Title
The Effect of Nebulization of Alkaline Solution on Treating XDRAB Pneumonia With C/S Plus Minocycline
Acronym
NAEDRAP
Official Title
The Effect of Nebulization of Alkaline Solution on Treating Extensively Drug Resistant A. Baumannii Pneumonia With Cefoperazone and Sulbactam Plus Minocycline: A Multi-center Randomized Study
Study Type
Interventional

2. Study Status

Record Verification Date
February 2014
Overall Recruitment Status
Unknown status
Study Start Date
March 2014 (undefined)
Primary Completion Date
March 2015 (Anticipated)
Study Completion Date
April 2015 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Xijing Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The mortality of pneumonia with extensively drug resistant Acinetobacter baumannii (XDRAB) is still high, even if these patients received certain strong anti-infection treatment such us the combination of cefoperazone-sulbactam (C/S) and minocycline. Health airway lining fluid is mildly alkaline but airway acidification usually appears for the infection of XDRAB. The hypothesis is offered that the biologic activity of XDRAB might be inhibited if the circumstance including pH is changed. In the vitro study we observed that the inhibit effect of antibiotics on XDRAB growth was improved significantly by alkaline solution within the scope of physiology. So the aim of this clinical study is to explore the effects of nebulization of alkaline Solution on C/S plus minocycline on the pneumonia with XDRAB.
Detailed Description
Pneumonia patients with XDRAB are eligible for this multicenter study, do not meet the exclusion criteria and will sign the informed consent. They will received the anti-infection protocol with Cefoperazone/ sulbactam 3.0g(intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h). All enrolled patients were randomly divided into three groups according to the difference in pH value of aerosol inhalation with sodium bicarbonate solution. Group one is blank-control and patients will received usual antibiotic treatment without inhalation. The pH value in group two is 7.4 and that in group is 7.8. Each time the volume of aerosol solution is 5ml, q8h. The average course of treatment will be two weeks. Clinical indexes will be collected including vital signs, pulmonary rales, cough level, expectoration level, sputum color,blood count, arterial blood gas, biochemical parameters, chest X-ray score, APACHE II score, clinical pulmonary infection score, ECG, sputum culture, et al.The primary endpoints are pathogenic clearance rate and recovery rate. The secondary end point is adverse reaction rate.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pneumonia
Keywords
Extensively Drug Resistant A. Baumannii

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
Participant
Allocation
Randomized
Enrollment
90 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
no nebulization
Arm Type
Sham Comparator
Arm Description
Antibiotics protocol is C/S plus minocycline. That is Cefoperazone/ sulbactam 3.0g(intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral,q12h).No nebulization will given to these patients.
Arm Title
nebulization with pH 7.4 solution
Arm Type
Active Comparator
Arm Description
Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.4 solution(Each time the volume of aerosol solution is 5ml, q8h).
Arm Title
nebulization with pH 7.8 solution
Arm Type
Experimental
Arm Description
Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.8 solution(Each time the volume of aerosol solution is 5ml, q8h).
Intervention Type
Drug
Intervention Name(s)
C/S plus minocycline.
Other Intervention Name(s)
CEFOPERAZONE SODIUM AND SULBACTAM SODIUM FOR INJECTION
Intervention Description
Cefoperazone/ sulbactam 3.0g(intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).
Intervention Type
Drug
Intervention Name(s)
nebulization with pH 7.4 solution
Other Intervention Name(s)
Sodium Bicarbonate
Intervention Description
Patients will receive the nebulization with Sodium Bicarbonate of pH 7.4 (Each time the volume of aerosol solution is 5ml, q8h).
Intervention Type
Drug
Intervention Name(s)
nebulization with pH 7.8 solution
Other Intervention Name(s)
Sodium Bicarbonate
Intervention Description
Patients will receive the nebulization with Sodium Bicarbonate of pH 7.8 (Each time the volume of aerosol solution is 5ml, q8h).
Intervention Type
Drug
Intervention Name(s)
No nebulization
Other Intervention Name(s)
sham
Intervention Description
No nebulization will be given to the patients.
Primary Outcome Measure Information:
Title
Pathogenic Clearance rate and recovery rate
Time Frame
one treatment course for about two weeks
Secondary Outcome Measure Information:
Title
adverse reaction rate
Time Frame
one treatment course for about two weeks
Other Pre-specified Outcome Measures:
Title
hospital time and mortality
Time Frame
about four weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age: 18 to 75 years old, male or female The pneumonia patients met the diagnostic criteria, and clinical pulmonary infection score (CPIS) ≥ 5; The sputum bacteriology detection only prompted Acinetobacter baumannii culture for pathogens concentration meets the diagnostic criteria of the Chinese hospital-acquired pneumonia diagnosis and treatment guidelines, 2002 edition of "Acinetobacter baumannii and susceptibility results show only 1 to 2 sensitive to antimicrobial drugs (polymyxin, minocycline or tegafur doxycycline); Cephalosporins or tetracyclines drug treatment without a history of allergies and contraindications; Be able to accept inhalation therapy. Informed consent gained Exclusion Criteria: Refused to accept inhalation therapy Renal insufficiency, creatinine clearance (Cockcroft-Gault formula) (CLcr) 15 ml / min or less; Liver dysfunction, defined as Child-Pugh score B or C Within one week before the start of cefoperazone sulbactam, minocycline treatment.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Juan Wang, master
Phone
18909233806
Email
ddys1211@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
liqiang song, doctor
Organizational Affiliation
first affiliated hospital, fourth military medical university
Official's Role
Principal Investigator
Facility Information:
Facility Name
Xijing Hospital
City
Xi'an
State/Province
Shaanxi
ZIP/Postal Code
710032
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
zhikui li, doctor
Phone
13571855922
Email
lizhikui@fmmu.edu.cn

12. IPD Sharing Statement

Learn more about this trial

The Effect of Nebulization of Alkaline Solution on Treating XDRAB Pneumonia With C/S Plus Minocycline

We'll reach out to this number within 24 hrs